Therapeutic area data reported by biopharma companies on phase I trials in October 2019.

Therapeutic area data reported by biopharma companies on phase II trials in October 2019.

Therapeutic area data reported by biopharma companies on phase III trials in October 2019.

The top 10 biopharma stock gainers and losers for the week of Nov. 4-8, 2019.

All of the biopharma stocks tracked by BioWorld, including their weekly and year-to-date percent changes and weekly trading volumes.

The oncology field pioneered adaptive trial designs through efforts such as I-SPY 2 (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2), Puma Biotechnology Inc.’s phase II study of the pan-HER tyrosine kinase inhibitor neratinib (Nerlynx) as neoadjuvant therapy in metastatic breast cancer, and the ongoing multidrug, biomarker-driven non-small-cell lung cancer trial known as Lung-MAP.

Total raised in public, private and other financings of biotech companies, comparing 2019 vs. 2018.

Year-to-date money raised in public, private and other financings of biopharma companies.

Centogene BV filed to sell 4 million common shares on Nasdaq for between $14 and $16 in an IPO expected to raise $60 million at the midpoint.